scholarly journals A comparative study of efficacy, safety and compliance of intravenous ferric carboxymaltose versus iron sucrose in the treatment of iron deficiency anaemia of pregnancy

2021 ◽  
Vol 8 (4) ◽  
pp. 448-453
Author(s):  
Vathsala Kamath ◽  
Naimisha Reddy ◽  
Nishita Shettian
Keyword(s):  
Iron Deficiency ◽  
Pregnant Women ◽  
Iron Deficiency Anaemia ◽  
Intravenous Iron ◽  
Post Treatment ◽  
Oral Iron ◽  
Iron Sucrose ◽  
Ferric Carboxymaltose ◽  
Third Trimester ◽  
Deficiency Anaemia

Iron deficiency is the most common cause of anaemia worldwide and is associated with significant maternal and fetal morbidity. Current options for treatment include oral iron supplementation which can be ineffective and poorly tolerated, intravenous iron which can be used in patients who are intolerant to or unresponsive to oral iron and red blood cell transfusions which carry an inherent risk because of which it should be avoided. Intravenous iron therapy may reduce the requirement for allogenic blood transfusion. Ferric carboxymaltose is a new intravenous iron formulation promising to be more effective and as safe as iron sucrose. It may even have a better compliance as it offers the administration of a much higher iron dosage at a time.The study was designed to compare the efficacy and safety of IV ferric carboxymaltose versus iron sucrose in the treatment of iron deficiency anaemia of pregnant women with moderate anaemia in the second and third trimester.A hospital based randomized prospective study was done from July 2013 to June 2015 in the department of Obstetrics and Gynaecology, A.J. Institute of Medical Sciences, Mangalore. Baseline haemoglobin, peripheral smear and serum ferritin levels were measured to diagnose iron deficiency anaemia. 60 pregnant women who met the inclusion criteria and who formed the study subjects were randomly allocated into two groups comprising of 30 in Group C (Received ferric carboxymaltose) and 30 in Group S (Received iron sucrose). Outcome was assessed by measuring haemoglobin 3 weeks after treatment and a comparison of the safety and efficacy between the two groups was made. In the present study the commonest age group was 21 to 30 years: 80% in group C and 73.3% in group S and mean age of the study population in group C and S was comparable (25.2±3.54 vs 24.8±4.58 years). The socio demographic characteristics, obstetric history, vitals and pretreatment haemoglobin were comparable in both the groups (p>0.050). The post treatment haemoglobin levels in 63.3% of the women in group C compared to 46.7% in group S were found to be 11 or more and mean post treatment haemoglobin levels were comparable in group C and group S (11.016±0.789 vs 10.73±0.821 gm%; p=0.174). In the present study, post treatment mean increase in haemoglobin levels was noted between 2.0 to 2.5 gm% in 43.3% of the women in group C compared to 50.0% in group S. Ferric carboxymaltose administration in pregnant women in the second and third trimesters is well tolerated and is not associated with any clinical safety concerns. Both ferric carboxymaltose and iron sucrose have a comparable safety profile even when ferric carboxymaltose was administered in a much higher dosage compared to iron sucrose. Ferric carboxymaltose should be considered as the drug of choice, if i.v. iron treatment becomes necessary in the second or third trimester of pregnancy.

scholarly journals Evaluation of efficacy of injection ferric carboxymaltose in pregnant women

2020 ◽  
Vol 9 (7) ◽  
pp. 2900
Author(s):  
Rupali M. Sabale ◽  
Reena J. Wani ◽  
Rashmi Jalvee
Keyword(s):  
Iron Deficiency ◽  
Pregnant Women ◽  
Iron Deficiency Anaemia ◽  
Oral Treatment ◽  
Intravenous Iron ◽  
Oral Iron ◽  
Ferric Carboxymaltose ◽  
Iron Group ◽  
Deficiency Anaemia ◽  
Iv Iron

Background: Iron deficiency anaemia (IDA) continues to be a very common problem in developing countries leading to a spectrum of adverse events in pregnant women. The objective of this study was to determine the efficacy, side effects and tolerance of ferric carboxymaltose as compared to available iron preparations for the prophylaxis and treatment of mild to moderate iron deficiency anaemia during pregnancy.Methods: One-year clinical study (from June 2017 to May 2018). A total 100 patients were enrolled after matching inclusion and exclusion criteria. The efficacy assessment was performed during 4, 8, and 12 weeks of starting therapy. If the patient is not responding to therapy in either arm as documented by no rise or fall in haemoglobin levels patients may be removed from study for other therapy. Treatment duration up to 12 weeks. Safety and efficacy follow-up visit at 4, 8 and 12 weeks. Institutional ethics committee permission was taken.Results: On intra-group comparisons there was significant increase in haemoglobin levels at 8 and 12 weeks in oral iron group as compared to day 1 haemoglobin levels while there was significant increase in haemoglobin levels at 4, 8 and 12 weeks in IV iron group as compared to day 1 haemoglobin levels. On intergroup comparisons between oral and IV iron group, there was significant increase in haemoglobin levels at 4, 8 and 12 weeks in IV iron group as compared oral iron group haemoglobin levels.Conclusions: Intravenous iron therapy with ferric carboxymaltose causes significant improvement in haemoglobin more quickly and more effective in correcting iron deficiency anaemia in pregnancy compared to oral treatment in terms of increase in haemoglobin levels at 4, 8 and 12 weeks. Intravenous ferric carboxymaltose is safe and effective option for pregnant women with iron deficiency anaemia.

scholarly journals COMPARATIVE STUDY OF INTRAVENOUS IRON SUCROSE AND ORAL IRON IN IRON DEFICIENCY ANAEMIA AMONG PREGNANT WOMEN IN RURAL

2013 ◽  
Vol 2 (7) ◽  
pp. 695-701 ◽  
Author(s):  
Meenal C ◽  
Hiremath P.B ◽  
Nidhi Bansal ◽  
Thirunaaukarasu Thirunaaukarasu ◽  
Srikanth S ◽  
...  
Keyword(s):  
Iron Deficiency ◽  
Comparative Study ◽  
Pregnant Women ◽  
Iron Deficiency Anaemia ◽  
Intravenous Iron ◽  
Oral Iron ◽  
Iron Sucrose ◽  
Deficiency Anaemia

scholarly journals Study of outcome of the treatment with intravenous iron sucrose in moderately anaemic pregnant women

2019 ◽  
Vol 8 (9) ◽  
pp. 3480
Author(s):  
Kohila Kalimuthu ◽  
Vanusha Avudaithangam
Keyword(s):  
Standard Deviation ◽  
Iron Deficiency ◽  
Pregnant Women ◽  
Iron Deficiency Anaemia ◽  
Intravenous Iron ◽  
Iron Sucrose ◽  
P Value ◽  
Deficiency Anaemia ◽  
The Mean ◽  
The Difference

Background: Moderate anaemia seen in about 15-20% of pregnant women. Iron sucrose complex which is used intravenously for the correction of Iron deficiency anaemia. The drug has been able to raise the haemoglobin to satisfactory level when used in moderately anaemic iron deficient pregnant women. The objective of this study was to study the improvement of Hb% after treatment with intravenous Iron sucrose complex in moderately anaemic pregnant women belonging to 24-32 weeks of gestational age.Methods: 50 antenatal patients between gestational age 24-32 weeks with hemoglobin between 8-9.5g/dl were selected and included in this study. They were subjected to blood hemoglobin estimation, hematocrit and peripheral smear study. In each infusion, the maximum total dose administered was 200 mg iron sucrose in 100 ml of normal saline, slow IV infused over 30 minutes. Monitoring was done throughout the infusion to observe for any side effects.Results: Mean hemoglobin among the 50 patients before starting the therapy was 8.172g/dl and the mean hemoglobin at the end of one month of completing the therapy was 11.066g/dl. The rise in mean hemoglobin i.e. the difference in the mean hemoglobin before and after treatment was 2.894g/dl. The p value is 0.0001 which is statistically significant. The mean hematocrit of the 50 patients studied before starting the treatment was 26.772% with a standard deviation of 1.914. The mean hematocrit after completing the therapy was 33.872% with a standard deviation of 1.321. The difference in the mean hematocrit was 7.100% with a p value of 0.0001 which is statistically significant.Conclusions: Intravenous iron sucrose complex is well tolerated and highly efficacious in improving hemoglobin, hematocrit in the treatment of iron deficiency anaemia in antenatal women.

scholarly journals Comparative study of efficacy and safety of intravenous ferric carboxymaltose versus iron sucrose in treatment of post-partum anemia

2021 ◽  
Vol 10 (9) ◽  
pp. 3531
Author(s):  
Ragvi Raman ◽  
Jayanthy T. ◽  
Apoorva Asranna
Keyword(s):  
Iron Deficiency Anaemia ◽  
Intravenous Iron ◽  
Post Treatment ◽  
Iron Sucrose ◽  
Ferric Carboxymaltose ◽  
Postpartum Women ◽  
Deficiency Anaemia ◽  
Group A ◽  
The Mean ◽  
Group B

Background: Ferric carboxymaltose has been recently introduced for the treatment of anaemia. The present study was planned to compare the efficacy, tolerability and safety of intravenous ferric carboxymaltose with intravenous iron sucrose in the treatment of iron deficiency anaemia among postpartum women.Methods: A total of 60 postpartum women with haemoglobin levels between 7-10 g/dl were randomized into two groups: 30 in group A (received iron carboxymaltose) and 30 in group B (Received iron sucrose). Haemoglobin and serum ferritin levels were done on day 0 and after 6 weeks.Results: The post treatment haemoglobin levels were found to be 10-10.9 g/dl in 66.7% of women in group A and 63.3% in group B. The mean post treatment haemoglobin levels in group A was 9.97±0.3 g/dl and in group B was 10.9 g/dl (p<0.001). The mean increase in haemoglobin levels post treatment were significantly high in group B (2.1±0.5 gm%) compared to group A (1.3±0.5 gm%). The mean post treatment S. Ferritin levels in group A was 91.2±25.8 and in group B was 126.5±23.2 gm%. The mean increase in S. Ferritin levels post treatment were significantly high in group B (96.9±23.3) compared to group A (62.7±22.6) (p<0.001).Conclusions: Intravenous iron carboxymaltose is more effective and better tolerated in the treatment of iron deficiency anaemia among postpartum women compared to intravenous iron sucrose.

Sign in / Sign up

Export Citation Format

Share Document